Novartis Pluvicto Delays Progression to End-Stage Prostate Cancer
According to PSMAddition data, Novartis Pluvicto has shown to delay progression to end-stage prostate cancer.
About Novartis
Novartis is an innovative medicines company that works to improve and extend people's lives, empowering patients, healthcare professionals, and societies in the face of serious disease.
- Their medicines reach 296 million people worldwide.
- Resources are available for patients, caregivers, physicians, and healthcare professionals, including clinical trial recruiting and grant funding.
Commitment to Society
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Discover more in the Novartis in Society Integrated Report.
We work to reimagine medicine to improve and extend people’s lives.
Author's summary: Novartis Pluvicto delays prostate cancer progression.
More News
- Monaco 1-0 PSG: Minamino’s Goal Ends Champions’ Winning Streak
- Chasing Olympic Gold at 80 Miles an Hour at 41? Only Lindsey Vonn.
- Qatar GP dates, UK start time and Sky Sports F1's live schedule - Sprint, Qualifying and Race
- Guide to Watching Fenerbahçe vs Galatasaray Live Streams and TV Broadcast
- Ski Legend Lindsey Vonn Shows Off Her High-Altitude Glow After Colorado Training Camp
- Definition and Meaning of the Word “Seeing”
- Lindsey Vonn's Retirement: The Painful Journey of a Skiing Legend and Her Path to Comeback
- Opening Plenary: Defending the Future of Free Media in the 21st Century
- Bears beat defending champs Eagles with dominant rushing performance
- Why Lindsey Vonn Thinks This Winter Olympics Might Be the Toughest Yet